2 Under-the-Radar Stocks That Could Soar
While oncology is the largest therapeutic area in the pharmaceutical industry by revenue, the anti-obesity space has grabbed the most attention over the past couple of years. This niche is still in its infancy, though, and it is projected to grow rapidly at least through the end of the decade. Many drugmakers, both large and small, are seeking to make a significant impact in this area. The most successful ones will reap substantial financial benefits and perhaps generate market-crushing returns in the process.
Two relatively unknown biotechs that are developing promising therapies in this field are Terns Pharmaceuticals (NASDAQ: TERN) and Rhythm Pharmaceuticals (NASDAQ: RYTM). These biotechs could soar provided they deliver solid progress. Here's what investors need to know.
Image source: Getty Images.
Source Fool.com
